October 18, 2017
Critical Outcome Technologies announced the closing of the second tranche of a $2 million non-brokered private placement.
September 7, 2017
Critical Outcome Technologies announced their president and CEO Alison Silva will co-chair the Global Genes RARE Partnering & Investor Forum.
August 14, 2017
Critical Outcome Technologies announced the completion of the dose escalation portion of their Phase 1 study of COTI-2.
April 13, 2017
Should you decide that the TSXV is right for you, the Investing News Network has compiled a list of some...
January 18, 2017
Three emerging biotech companies took to the Cantech Investment Conference stage: ProMIS Neurosciences, RepliCel Life Sciences and Critical Outcome Technologies.
October 12, 2016
Critical Outcome Technologies, a clinical-stage biopharmaceutical company advancing innovative and targeted therapies for the treatment of cancer, announced today that...
August 3, 2016
LONDON, ON–(Marketwired – August 03, 2016) – Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX VENTURE: COT) (OTCQB: COTQF),...